Similar articles for PMID: 24591668

Year	Number of Results
2009	1
2010	3
2011	8
2012	2
2013	9
2014	11
2015	12
2016	8
2017	13
2018	5
2019	19
2020	13
2021	10
2022	1
2023	1
2024	0

1

Pirfenidone: an update on clinical trial data and insights from everyday practice.

Kreuter M. Kreuter M. Eur Respir Rev. 2014 Mar 1;23(131):111-7. doi: 10.1183/09059180.00008513. Eur Respir Rev. 2014. PMID: 24591668 Free PMC article. Review.

2

Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients?

Costabel U. Costabel U. Eur Respir Rev. 2011 Sep 1;20(121):201-7. doi: 10.1183/09059180.00002011. Eur Respir Rev. 2011. PMID: 21881148 Free PMC article. Review.

3

Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.

Feng H, Zhao Y, Li Z, Kang J. Feng H, et al. Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620963015. doi: 10.1177/1753466620963015. Ther Adv Respir Dis. 2020. PMID: 33070705 Free PMC article.

4

The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial.

Taniguchi H, Kondoh Y, Ebina M, Azuma A, Ogura T, Taguchi Y, Suga M, Takahashi H, Nakata K, Sato A, Sugiyama Y, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan. Taniguchi H, et al. Respir Res. 2011 Jul 15;12(1):93. doi: 10.1186/1465-9921-12-93. Respir Res. 2011. PMID: 21756364 Free PMC article. Clinical Trial.

5

Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program.

Richeldi L, du Bois RM. Richeldi L, et al. Expert Rev Respir Med. 2011 Aug;5(4):473-81. doi: 10.1586/ers.11.52. Expert Rev Respir Med. 2011. PMID: 21859266 Review.

6

Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.

Costabel U, Albera C, Bradford WZ, Hormel P, King TE Jr, Noble PW, Sahn SA, Valeyre D, du Bois RM. Costabel U, et al. Sarcoidosis Vasc Diffuse Lung Dis. 2014 Oct 20;31(3):198-205. Sarcoidosis Vasc Diffuse Lung Dis. 2014. PMID: 25363219 Clinical Trial.

7

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.

Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U. Lancaster LH, et al. Eur Respir Rev. 2017 Dec 6;26(146):170057. doi: 10.1183/16000617.0057-2017. Print 2017 Dec 31. Eur Respir Rev. 2017. PMID: 29212837 Free PMC article. Review.

8

Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.

Azuma A. Azuma A. Expert Rev Respir Med. 2010 Jun;4(3):301-10. doi: 10.1586/ers.10.32. Expert Rev Respir Med. 2010. PMID: 20524912 Review.

9

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.

Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzke DR, Daigl M, Kirchgaessler KU, Lancaster LH, Lederer DJ, Pereira CA, Swigris JJ, Valeyre D, Noble PW. Nathan SD, et al. Lancet Respir Med. 2017 Jan;5(1):33-41. doi: 10.1016/S2213-2600(16)30326-5. Epub 2016 Nov 19. Lancet Respir Med. 2017. PMID: 27876247

10

Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential.

Raghu G. Raghu G. Eur Respir Rev. 2017 Sep 27;26(145):170071. doi: 10.1183/16000617.0071-2017. Print 2017 Sep 30. Eur Respir Rev. 2017. PMID: 28954769 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

100 results

Results by year